CVE:HEM Hemostemix Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Hemostemix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. C$0.26 +0.01 (+2.00%) (As of 06/30/2022 11:26 AM ET) Add Compare Share Today's RangeC$0.25▼C$0.2650-Day RangeC$0.25▼C$0.3852-Week RangeC$0.13▼C$0.42Volume21,300 shsAverage Volume104,995 shsMarket CapitalizationC$17.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsInsider TradesHeadlinesSocial Media Hemostemix MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling SharesC$93.21 K Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.39 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Hemostemix. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for HEM. Previous Next 0.0 Dividend Strength Dividend YieldHemostemix does not currently pay a dividend.Dividend GrowthHemostemix does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HEM. Previous Next 1.1 News and Social Media Coverage News SentimentHemostemix has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hemostemix insiders have sold 1,453.50% more of their company's stock than they have bought. Specifically, they have bought C$6,000.00 in company stock and sold C$93,210.00 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Hemostemix is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Hemostemix is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter. Email Address About Hemostemix (CVE:HEM) StockHemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.Read More HEM Stock News HeadlinesJune 14, 2022 | finanznachrichten.deHemostemix Inc.: Hemostemix Announces the Incorporation of PreCerv Inc. And a Global Field of Use License to NCP-01June 14, 2022 | finance.yahoo.comHemostemix Announces the Incorporation of PreCerv Inc. And a Global Field of Use License to NCP-01June 7, 2022 | finanznachrichten.deDelveInsight Business Research, LLP: Critical Limb Ischemia Market to Progress at a CAGR of 10.6% by 2030 | DelveInsightJune 7, 2022 | finance.yahoo.comCritical Limb Ischemia Market to Progress at a CAGR of 10.6% by 2030 | DelveInsightMay 19, 2022 | finance.yahoo.comHemostemix Announces Pete Pavlin, P.Eng., Vice-President OperationsMay 16, 2022 | finance.yahoo.comHemostemix Announces Rick Groome as Special Advisor to The CEOMay 11, 2022 | ca.finance.yahoo.comHemostemix, Leucrotta Lone Stocks at 52-Week HighsMay 10, 2022 | finance.yahoo.comHemostemix Announces Its Intellectual Property is Back HomeApril 12, 2022 | finance.yahoo.comHemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit CompletedMarch 23, 2022 | finance.yahoo.comHemostemix Announces Settlement AgreementMarch 16, 2022 | proactiveinvestors.comHemostemix using cell therapy to aid in the fight against cardiovascular diseaseMarch 2, 2022 | finanznachrichten.deHemostemix Inc.: Hemostemix Announces Closing of UNIT Private PlacementMarch 2, 2022 | ca.finance.yahoo.comHemostemix Announces $2,750,000 Convertible DebentureMarch 1, 2022 | finance.yahoo.comHemostemix Announces Stock Options GrantFebruary 14, 2022 | finanznachrichten.deHemostemix Inc.: Your Fountain of Youth Trademarked by HemostemixFebruary 2, 2022 | finance.yahoo.comHemostemix Announces FinancingJanuary 11, 2022 | finanznachrichten.deHemostemix Inc.: Hemostemix to Combine ACP-01 with Dr. James Shapiro's Islet Cells to Treat Type 1 DiabetesDecember 9, 2021 | finance.yahoo.comHemostemix Announces Soft Lock of Database as Source Document Verification CompletedOctober 28, 2021 | finance.yahoo.comHemostemix Confirms OTCQB ListingOctober 19, 2021 | finance.yahoo.comHemostemix Confirms OTCQB Application is FiledOctober 14, 2021 | ca.finance.yahoo.comHemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical OfficerOctober 4, 2021 | finance.yahoo.comHemostemix Announces the Second Stem Cell Recipient Interview: One Week to No Chest PainSeptember 21, 2021 | finance.yahoo.comHemostemix Announces Closing of First Tranche of Unit Private PlacementSeptember 9, 2021 | ca.finance.yahoo.comBiden moves to oust Trump military academy board appointeesSeptember 8, 2021 | ca.finance.yahoo.comHemostemix Announces Five Million Unit Private PlacementSee More Headlines Industry, Sector and Symbol Stock ExchangeCVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:HEM CUSIPN/A CIKN/A Webwww.hemostemix.com Phone+1-403-3409207FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.25 Quick Ratio0.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.01 per share Price / Cash Flow18.21 Book ValueC($0.08) per share Price / Book-3.15Miscellaneous Outstanding Shares68,253,000Free FloatN/AMarket CapC$17.40 million OptionableNot Optionable BetaN/A Hemostemix Frequently Asked Questions How has Hemostemix's stock price performed in 2022? Hemostemix's stock was trading at C$0.16 on January 1st, 2022. Since then, HEM shares have increased by 59.4% and is now trading at C$0.26. View the best growth stocks for 2022 here. Who are Hemostemix's key executives? Hemostemix's management team includes the following people: Mr. Thomas A. Smeenk B.A., BA Hons, Co-Founder, Pres, CEO & Director (Age 60, Pay $277.08k)Ms. Christina Wu CPA, Interim Chief Financial OfficerDr. Fraser C. Henderson Sr., M.D., Chief Medical Officer Who are some of Hemostemix's key competitors? Some companies that are related to Hemostemix include Microbix Biosystems (MBX), Covalon Technologies (COV), Pediapharm (PDP), Sirona Biochem (SBM), Resverlogix (RVX), Heat Biologics (HTBX), Synairgen (SNG), ProMIS Neurosciences (PMN), Medigene (MDG1), Burcon NutraScience (BU), Devonian Health Group (GSD), Asterias Biotherapeutics (AST), Emerald Health Therapeutics (EMH), C4X Discovery (C4XD) and 4basebio (4BB). View all of HEM's competitors. What other stocks do shareholders of Hemostemix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hemostemix investors own include Iplayco (IPC), Capricor Therapeutics (CAPR), Gene Biotherapeutics (CRXM), Camber Energy (CEI), Auxly Cannabis Group (CBWTF), Cannabis Science (CBIS), Beazer Homes USA (BZH), Big Tree Group (BIGG), Asterias Biotherapeutics (AST) and (AQB). What is Hemostemix's stock symbol? Hemostemix trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HEM." How do I buy shares of Hemostemix? Shares of HEM and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Hemostemix's stock price today? One share of HEM stock can currently be purchased for approximately C$0.26. How much money does Hemostemix make? Hemostemix (CVE:HEM) has a market capitalization of C$17.40 million. How can I contact Hemostemix? Hemostemix's mailing address is Bay 1, PO Box 10, BLACKFALDS, AB T0M 0J0, Canada. The official website for Hemostemix is www.hemostemix.com. The biotechnology company can be reached via phone at +1-403-3409207. This page (CVE:HEM) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
